TSS
FTH

Two Sigma Securities’s Faeth Therapeutics FTH Stock Holding History

Two Sigma Securities’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-930
Closed -$11.5K – 3569
2024
Q2 		$11.5K Buy
+930
New +$19.3K ﹤0.01% 2790

Other funds holding FTH

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Securities's FTH Position: Q3 2024 in Review

Two Sigma Securities sold out of Faeth Therapeutics (FTH) in Q3 2024, closing a stake of 930 shares — an estimated $11.5K sold.

Two Sigma Securities first reported a position in FTH in Q2 2024 and held it in 1 quarter. The position peaked at $11.5K in Q2 2024. 19 funds tracked by Wall St. Rank hold FTH as of Q3 2024.

  • Two Sigma Securities reported no remaining Faeth Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Securities sold 930 Faeth Therapeutics shares in Q3 2024, an estimated $11.5K.
  • Two Sigma Securities first reported a position in Faeth Therapeutics in Q2 2024 and held it in 1 quarter.
  • Two Sigma Securities's Faeth Therapeutics position peaked at $11.5K in Q2 2024.
  • 19 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2024.

Based on Two Sigma Securities's 13F filing for Q3 2024, filed 14 Nov 2024.